Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease.

Beaudoin JJ, Bezen├žon J, Cao Y, Mizuno K, Roth SE, Brock WJ, Brouwer KLR.

Drug Metab Dispos. 2019 Feb;47(2):155-163. doi: 10.1124/dmd.118.083907. Epub 2018 Nov 30. Erratum in: Drug Metab Dispos. 2019 Mar;47(3):328.

PMID:
30504136
2.

Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease.

Brock WJ, Beaudoin JJ, Slizgi JR, Su M, Jia W, Roth SE, Brouwer KLR.

Int J Toxicol. 2018 Mar/Apr;37(2):144-154. doi: 10.1177/1091581818760746.

PMID:
29587557
3.

miR-122 Release in Exosomes Precedes Overt Tolvaptan-Induced Necrosis in a Primary Human Hepatocyte Micropatterned Coculture Model.

Mosedale M, Eaddy JS, Trask OJ Jr, Holman NS, Wolf KK, LeCluyse E, Ware BR, Khetani SR, Lu J, Brock WJ, Roth SE, Watkins PB.

Toxicol Sci. 2018 Jan 1;161(1):149-158. doi: 10.1093/toxsci/kfx206.

4.

Editor's Highlight: Candidate Risk Factors and Mechanisms for Tolvaptan-Induced Liver Injury Are Identified Using a Collaborative Cross Approach.

Mosedale M, Kim Y, Brock WJ, Roth SE, Wiltshire T, Eaddy JS, Keele GR, Corty RW, Xie Y, Valdar W, Watkins PB.

Toxicol Sci. 2017 Apr 1;156(2):438-454. doi: 10.1093/toxsci/kfw269.

5.

Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors.

Woodhead JL, Brock WJ, Roth SE, Shoaf SE, Brouwer KL, Church R, Grammatopoulos TN, Stiles L, Siler SQ, Howell BA, Mosedale M, Watkins PB, Shoda LK.

Toxicol Sci. 2017 Jan;155(1):61-74. doi: 10.1093/toxsci/kfw193. Epub 2016 Sep 21.

6.

Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes.

Lu Y, Slizgi JR, Brouwer KR, Claire RL, Freeman KM, Pan M, Brock WJ, Brouwer KL.

Drug Metab Dispos. 2016 Jun;44(6). pii: dmd.115.067629. doi: 10.1124/dmd.115.067629. Epub 2016 Mar 24.

7.

Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?

Slizgi JR, Lu Y, Brouwer KR, St Claire RL, Freeman KM, Pan M, Brock WJ, Brouwer KL.

Toxicol Sci. 2016 Jan;149(1):237-50. doi: 10.1093/toxsci/kfv231. Epub 2015 Oct 26.

8.

Age-Related Alterations in Blood Biochemical Characterization of Hepatorenal Function in the PCK Rat: A Model of Polycystic Kidney Disease.

Shimomura Y, Brock WJ, Ito Y, Morishita K.

Int J Toxicol. 2015 Nov-Dec;34(6):479-90. doi: 10.1177/1091581815611075. Epub 2015 Oct 25.

PMID:
26503599
9.

Scientific conduct... and misconduct.

Genter MB, Brock WJ, Mattes WB.

Toxicol Sci. 2015 Mar;144(1):3-4. No abstract available.

PMID:
25901331
10.

Strengthening the peer review process for the International Journal of Toxicology.

Brock WJ.

Int J Toxicol. 2014 Sep-Oct;33(5):351-2. No abstract available.

PMID:
25513055
11.

Strengthening the peer review process for the International Journal of Toxicology.

Brock WJ.

Int J Toxicol. 2014 Sep-Oct;33(5):351-2. No abstract available.

PMID:
25436270
12.

Ocular toxicity assessment from systemically administered xenobiotics: considerations in drug development.

Brock WJ, Somps CJ, Torti V, Render JA, Jamison J, Rivera MI.

Int J Toxicol. 2013 May-Jun;32(3):171-88. doi: 10.1177/1091581813484500. Epub 2013 Apr 24. Review.

PMID:
23616147
13.

The in vitro and in vivo genotoxicity of benzocaine: a brief communication.

Brock WJ, Bell TA.

Int J Toxicol. 2012 Jun;31(3):222-7. doi: 10.1177/1091581812442230. Epub 2012 May 2.

PMID:
22556388
14.

Oral repeat dose and reproductive toxicity of the chlorinated flame retardant Dechlorane Plus.

Brock WJ, Schroeder RE, McKnight CA, VanSteenhouse JL, Nyberg JM.

Int J Toxicol. 2010 Dec;29(6):582-93. doi: 10.1177/1091581810384154. Epub 2010 Oct 19.

PMID:
20959615
15.

Certification in toxicology: an international perspective of risk:benefit.

Brock WJ, Woolley AP, Sugimoto T.

Int J Toxicol. 2009 May-Jun;28(3):147-50. No abstract available.

PMID:
19650207
16.
17.

Food safety: risk assessment methodology and decision-making criteria.

Brock WJ, Rodricks JV, Rulis A, Dellarco VL, Gray GM, Lane RW.

Int J Toxicol. 2003 Nov-Dec;22(6):435-51.

PMID:
14680991
18.

Developmental toxicity and genotoxicity studies of 1,1,1,3,3,3-hexachloropropane (HCC-230fa) in rats.

Brock WJ, Munley SM, Swanson MS, McGown KM, Hurtt ME.

Toxicol Sci. 2003 Oct;75(2):448-57. Epub 2003 Jul 25.

PMID:
12883086
19.

Cardiac sensitization: methodology and interpretation in risk assessment.

Brock WJ, Rusch GM, Trochimowicz HJ.

Regul Toxicol Pharmacol. 2003 Aug;38(1):78-90. Review.

PMID:
12878057
20.

Effects of HCFC-123 exposure to maternal and infant rhesus monkeys on hepatic biochemistry, lactational parameters and postnatal growth.

Cappon GD, Keller DA, Brock WJ, Slauter RW, Hurtt ME.

Drug Chem Toxicol. 2002 Nov;25(4):481-96.

PMID:
12378954
21.

Subchronic inhalation toxicity of the chlorinated propane 1,1,1,3,3,3-hexachloropropane (HCC-230fa).

Bamberger JR, Ladics GS, Hurtt ME, Swanson MS, Brock WJ.

Toxicol Sci. 2001 Jul;62(1):155-65.

PMID:
11399803
22.

Setting safe acute exposure limits for halon replacement chemicals using physiologically based pharmacokinetic modeling.

Vinegar A, Jepson GW, Cisneros M, Rubenstein R, Brock WJ.

Inhal Toxicol. 2000 Aug;12(8):751-63.

PMID:
10880155
23.

Inhalation toxicity and genotoxicity of hydrochlorofluorocarbon (HCFC)-225ca and HCFC-225cb.

Brock WJ, Shin-Ya S, Rusch GM, Hardy CJ, Trochimowicz HJ.

J Appl Toxicol. 1999 Mar-Apr;19(2):101-12.

PMID:
10215182
24.

Chronic toxicity, oncogenicity, and mutagenicity studies with chlorotetrafluoroethane (HCFC-124).

Malley LA, Frame SR, Elliott GS, Bentley KS, Brock WJ, Trochimowicz HJ, Rusch GM.

Drug Chem Toxicol. 1998 Nov;21(4):417-47.

PMID:
9839154
26.

Acute, subchronic, and developmental toxicity and genotoxicity of 1,1,1-trifluoroethane (HFC-143a).

Brock WJ, Trochimowicz HJ, Farr CH, Millischer RJ, Rusch GM.

Fundam Appl Toxicol. 1996 Jun;31(2):200-9.

PMID:
8789786
27.

Acute and subchronic toxicity of 1,1-dichloro-1-fluoroethane (HCFC-141b).

Brock WJ, Trochimowicz HJ, Millischer RJ, Farr C, Kawano T, Rusch GM.

Food Chem Toxicol. 1995 Jun;33(6):483-90.

PMID:
7797175
28.

Hepatic macromolecular binding and tissue distribution of ortho- and para-toluidine in rats.

Brock WJ, Hundley SG, Lieder PH.

Toxicol Lett. 1990 Dec;54(2-3):317-25.

PMID:
1701932
29.

Linking health care for the poor to health care for profit.

Wolfson J, Levin PJ, Brock WJ.

Health Aff (Millwood). 1987 Spring;6(1):129-35. No abstract available.

PMID:
3583213
30.

Characterization of covalent binding of N'-nitrosonornicotine in rat liver microsomes.

Hughes MF, Brock WJ, Marion LJ, Vore M.

Carcinogenesis. 1986 Jan;7(1):3-8.

PMID:
3510749
31.
33.

Characterization of uptake of steroid glucuronides into isolated male and female rat hepatocytes.

Brock WJ, Vore M.

J Pharmacol Exp Ther. 1984 Apr;229(1):175-81.

PMID:
6707932
35.

Obstinate Vomiting in Pregnancy.

Brock WJ.

Glasgow Med J. 1883 Mar;19(3):198-210. No abstract available.

36.

Obstinate Vomiting in Pregnancy.

Brock WJ.

Trans Edinb Obstet Soc. 1883;8:60-72. No abstract available.

Supplemental Content

Loading ...
Support Center